繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNP-630

SNP-630

Indication
Non-alcoholic steatohepatitis (NASH)
Product Advantages
1. Optimized New Chemical Entity
2. First-in-class
3. For NASH and ASH
Status
1. Pre-clinical
2. SNP-630 and/or its active metabolites: some human experience
3. Plan to apply US FDA IND, fast track and breakthrough designation
Competitive Edge
1. Multiple mechanisms of action
2. Direct action on liver
3. Optimal potency
4. Great safety profile
Potential Market
The estimated global market for NASH: 35-40 B per year

Multiple Mechanisms of Action of SNP-6xx


玩ag电子游戏被黑钱